Research Paper Volume 13, Issue 5 pp 7020—7034

The efficiency and safety of high-dose vitamin C in patients with COVID-19: a retrospective cohort study

Changes in hs-CRP and PCT levels with therapy. (A) High-dose vitamin C reduced serum hs-CRP levels in COVID-19 patients; (B) High-dose vitamin C reduced serum PCT levels in COVID-19 patients; (C) High-dose vitamin C did not affect the serum IL-2R levels in COVID-19 patients remarkably; (D) High-dose vitamin C did not affect the serum IL-6 levels in COVID-19 patients remarkably; (E) High-dose vitamin C reduced serum IL-8 levels in COVID-19 patients; (F) High-dose vitamin C did not affect the serum TNF-α in COVID-19 patients remarkably. VitC: vitamin C; hs-CRP: high-sensitivity C-reactive protein; PCT: procalcitonin; IL-2R: interleukin-2 receptor; IL-6: interleukin-6; IL-8: interleukin-8; TNF-α: tumor necrosis factor-α levels.

Figure 3. Changes in hs-CRP and PCT levels with therapy. (A) High-dose vitamin C reduced serum hs-CRP levels in COVID-19 patients; (B) High-dose vitamin C reduced serum PCT levels in COVID-19 patients; (C) High-dose vitamin C did not affect the serum IL-2R levels in COVID-19 patients remarkably; (D) High-dose vitamin C did not affect the serum IL-6 levels in COVID-19 patients remarkably; (E) High-dose vitamin C reduced serum IL-8 levels in COVID-19 patients; (F) High-dose vitamin C did not affect the serum TNF-α in COVID-19 patients remarkably. VitC: vitamin C; hs-CRP: high-sensitivity C-reactive protein; PCT: procalcitonin; IL-2R: interleukin-2 receptor; IL-6: interleukin-6; IL-8: interleukin-8; TNF-α: tumor necrosis factor-α levels.